Tag Archive for: clinical data

Resolution Therapeutics announces new data showcasing the potential of Regenerative Macrophage Therapy in treating cirrhosis at AASLD 2025

/in

New clinical data from the MATCH Phase II study shows early improvement in liver function after treatment with non-engineered macrophages is associated with positive long term clinical outcomes New preclinical data from Resolution’s first engineered Regenerative Macrophage Therapy, RTX001, shows significant reduction of systemic inflammation Comes as Resolution progresses its Phase I/II EMERALD study of […]

Read more

Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma

/in

Evidence of clinical activity observed in Cohort 8, including stringent complete remission in two patients from Cohort 8 HDP-101 continues to demonstrate a favorable safety profile with no dose-limiting toxicities observed in Cohort 8 R&D Webinar to be hosted on 11 November 2025 at 05:00 pm CET (08:00 am PST) Ladenburg, Germany, 6 November 2025 […]

Read more

Vesper Bio announces positive Phase Ib/IIa topline results for lead candidate VES001 for frontotemporal degeneration

/in

Phase Ib/IIa study found VES001, the first oral therapy being tested in FTD, led to >95% mean increase in progranulin levels in CSF, compared to baseline Topline results indicate VES001 normalises levels of progranulin in people who have a shortage of this vital protein for genetic reasons, potentially stopping them developing symptomatic frontotemporal dementia (FTD) […]

Read more

Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma

/in

HDP-101 continues to demonstrate a favorable safety profile with no dose-limiting toxicities observed Early evidence of clinical activity observed in Cohort 8, highlighted by a very good partial response observed in one patient Ladenburg, Germany, 25 September 2025 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today […]

Read more

Xeltis poised for commercialization following excellent clinical data from aXess EU pivotal multicentre trial

/in

Complete EU pivotal trial data highlights transformative potential of aXess in hemodialysis treatment Primary endpoint met with standout sustained patency rates, with major improvements demonstrated across the board compared to standard of care Enhances clinical profile of aXess, reinforcing excellent first-in-human outcomes amid ongoing US pivotal trial and ahead of commercialization EINDHOVEN, The Netherlands, 24 […]

Read more